花旗：美国药价改革对印度制药股构成利空

Core Viewpoint - The potential U.S. drug price reform poses a negative outlook for Indian pharmaceutical stocks, despite the uncertainty surrounding the feasibility of Trump's plan to lower prescription drug prices [1] Summary by Relevant Categories Impact on Indian Pharmaceutical Companies - Indian pharmaceutical companies involved in brand and specialty drugs are expected to be the most affected by the potential price reductions of 30%-80% [1] - Generic drug manufacturers are likely to experience minimal impact from these proposed changes [1] U.S. Drug Pricing Context - The high cost of drugs in the U.S. is attributed to the insurance system and the profit margins of intermediaries [1] - Simply lowering surface prices may not effectively address the underlying issues of drug pricing in the U.S. [1]